Generic Name: Etoricoxib
Therapeutic Class: Selective COX-2 Inhibitor (NSAID)
Indications
Etoricoxib is used for the acute and chronic treatment of signs and symptoms of osteoarthritis and rheumatoid arthritis, as well as for the management of pain:
- Osteoarthritis (OA): Relief of chronic joint pain and stiffness.
- Rheumatoid Arthritis (RA): Management of inflammatory joint symptoms.
- Ankylosing Spondylitis: Reduction of pain and inflammation in the spine.
- Acute Gouty Arthritis: Rapid relief of severe pain and swelling during gout attacks.
- Acute Pain: Management of moderate to severe postoperative dental surgical pain and primary dysmenorrhea.
Dosage & Administration
Etoricoxib is administered orally and can be taken with or without food.
- Osteoarthritis: 30 mg or 60 mg once daily.
- Rheumatoid Arthritis & Ankylosing Spondylitis: 60 mg or 90 mg once daily.
- Acute Gouty Arthritis: 120 mg once daily, limited to a maximum of 8 days.
- Postoperative Dental Surgery Pain: 90 mg once daily, limited to a maximum of 3 days.
- Hepatic Impairment: In patients with mild hepatic insufficiency, the dose should not exceed 60 mg daily. In moderate insufficiency, it should not exceed 30 mg daily.
Description & Pharmacokinetics
Etoricoxib is a second-generation selective cyclooxygenase-2 (COX-2) inhibitor, designed to provide anti-inflammatory benefits with reduced gastrointestinal toxicity.
Mechanism of Action: It works by **highly selective inhibition of Cyclooxygenase-2 (COX-2)**. Unlike traditional NSAIDs (like Aspirin or Naproxen), it does not significantly inhibit COX-1 at therapeutic concentrations. COX-2 is primarily responsible for the synthesis of pro-inflammatory prostaglandins. By sparing COX-1, which protects the gastric mucosa and aids platelet function, Etoricoxib aims to reduce the risk of stomach ulcers.
Pharmacokinetics:
Mechanism of Action: It works by **highly selective inhibition of Cyclooxygenase-2 (COX-2)**. Unlike traditional NSAIDs (like Aspirin or Naproxen), it does not significantly inhibit COX-1 at therapeutic concentrations. COX-2 is primarily responsible for the synthesis of pro-inflammatory prostaglandins. By sparing COX-1, which protects the gastric mucosa and aids platelet function, Etoricoxib aims to reduce the risk of stomach ulcers.
Pharmacokinetics:
- Absorption: Well absorbed orally with an absolute bioavailability of approximately 100%.
- Peak Plasma Time: Approximately 1 hour ($T_{max}$) when taken fasting.
- Metabolism: Extensively metabolized in the liver, primarily by the **CYP3A4** enzyme.
- Elimination: Primarily excreted via the kidneys as metabolites. The elimination half-life is approximately 22 hours, supporting once-daily dosing.
Side Effects
- Cardiovascular: Hypertension (common), palpitations, and an increased risk of thrombotic events (myocardial infarction or stroke).
- Gastrointestinal: Alveolar osteitis (dry socket), abdominal pain, constipation, flatulence, and dyspepsia.
- Neurological: Headache, dizziness, and fatigue.
- Skin: Ecchymosis (bruising) and rare cases of Stevens-Johnson Syndrome.
- Other: Peripheral edema (fluid retention) and increased ALT/AST levels.
Extra Important Information: Usage Insights
- Blood Pressure Monitoring: Because Etoricoxib is associated with more frequent and severe hypertension than some other NSAIDs, BP should be monitored within two weeks of starting treatment.
- CV Safety: Selective COX-2 inhibitors may be associated with an increased risk of cardiovascular events; use the lowest effective dose for the shortest duration possible.
- Gastric Safety: While safer for the stomach than standard NSAIDs, risk still exists for those with a history of GI bleeds.
- Contraindications: Contraindicated in patients with active peptic ulceration, inflammatory bowel disease (IBD), or severe congestive heart failure.
Pregnancy & Lactation
- Pregnancy: Contraindicated in pregnancy. Like other inhibitors of prostaglandin synthesis, it may cause uterine inertia and premature closure of the ductus arteriosus.
- Lactation: It is not known whether Etoricoxib is excreted in human milk. Breastfeeding is not recommended during treatment.
Storage
Store at room temperature (below 30°C). Protect from light and moisture. Keep out of reach of children.
.png)
